Ocular Therapeutix to present 12-month top-line data from Phase 1 OTX-TKI trial for wet AMD at the 2023 Clinical Trials at the Summit Annual Meeting
Ocular Therapeutix is scheduled to present trial results as well as participate in a panel discussion and sponsor a presentation at the 2023 Clinical Trials at the Summit Annual Meeting.
Ocular Therapeutix is scheduled to present trial results at the 2023 Clinical Trials at the Summit Annual Meeting on June 10 in Park City, Utah. (Image Credit: Adobe Stock/SeanPavonePhoto)
Ocular Therapeutix, Inc. will present 12-month data from the U.S.-based phase 1 trial of OTX-TKI at the Clinical Trials at the Summit Annual Meeting. The meeting is being held on June 10, 2023 in Park City, Utah. Ocular Therapeutix is also sponsoring a presentation discussing the Company's proprietary bioresorbable hydrogel-based formulation technology and retina focused clinical programs. A conference call discussing the 12-month data from the U.S.-based Phase 1 clinical trial of OTX-TKI presented at the Clinical Trials at the Summit will be hosted by the Ocular Therapeutix management team on Monday, June 12th at 8:30 am ET.
“We look forward to presenting the 12-month data update from our U.S.-based trial evaluating OTX-TKI for the treatment of wet AMD,” stated Rabia Gurses Ozden, MD, Chief Medical Officer of Ocular Therapeutix in the press release. “Our most recent update at 10-months observed that CSFT and BCVA measurements at 10 months were comparable between OTX-TKI treated subjects and aflibercept treated subjects with a 92% reduction in treatment burden in the OTX-TKI arm. This new data will include additional information regarding the pharmacodynamics of OTX-TKI at month 12.”
Presentations at Clinical Trials at the Summit:
12-Month Update on Randomized, Controlled, Trial of OTX-TKI (Axitinib Intravitreal Implant) for the Treatment of Wet AMD
- Date / Time: Saturday, June 10th at 4:29 am MDT
- Presenter: Arshad M. Khanani, MD, Director of Clinical Research at Sierra Eye Associates
- The presentation will be posted on the Company’s website at approximately 4:30 pm MDT the same day under the Investors tab, Events and Presentations/Scientific and Medical Presentations.
Challenges of Bringing Novel Treatment Options to the Market
- Panel Date/Times: Saturday, June 10th at 10:44 am MDT
- Panelists: Mohamed Genead, Alexander Hardy, Antony Mattessich, Reenie McCarthy, Joel Naor, Victor Perlroth
- Moderator: Jeffrey Heier, MD, Director of the Vitreoretinal Service and Retina Research at Ophthalmic Consultants of Boston and member of the Board of Directors, Ocular Therapeutix, Inc.
Ocular Therapeutix: Transforming Ophthalmic Care with Innovative Therapies
- Sponsored presentation Date/Times: Saturday, June 10th at 5:03 pm MDT
- Presenter: Peter K. Kaiser, MD, Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine and Chief Medical Advisor, Retina at Ocular Therapeutix
